| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 559.09 | 6.2% | 37.0% |
| Total Income | 565.26 | 5.2% | 35.8% |
| Expenditure | 487.15 | 5.3% | 33.4% |
| PBT | 72.82 | 2.5% | 42.7% |
| Net Profit | 54.22 | 2.9% | 41.1% |
| OPM | 12.50% | 2.84pp | 4.36pp |
| NPM | 9.59% | 0.80pp | 0.36pp |
| EPS | 21.69 | 2.9% | 41.1% |
AstraZeneca Pharma India Ltd Reports Q3 2025 Financial Results with 542.2 Million Profit
07 Nov 2025 · 7 Nov 2025, 05:53 pm
Summary
AstraZeneca Pharma India Ltd has reported its Q3 2025 financial results with a profit of 542.2 million. The report was approved at the Board meeting held on November 7, 2025. The company's revenue from operations was 55909 and the total income was 56526. The profit before tax was 728.2 and the profit after tax was 542.2. The earnings per equity share of Rs 2/- each (basic and diluted) was 21.69.
Key Highlights
- 1
Q3 2025 profit of 542.2 million
- 2
Revenue from operations: 55909
- 3
Total income: 56526
- 4
Profit before tax: 728.2
- 5
Profit after tax: 542.2
- 6
Earnings per equity share: 21.69
- 7
Manufacturing site closure and sale process initiated
Management Comments
Praveen Rao Akkinepally
Statement of unaudited financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 7 November 2025.
Informational and educational content only. Not investment advice.